tbuckley/cabot-search huggingface dataset:
Contributions
Authors: James R. Baker
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.
Authors: Jose De La Cerda, Elizabeth Migoya, Bruce Brown, Sophia Lu, Fabian Zohren, Ronald F. Tutrone, Curtis Dunshee
Journal: Journal of Clinical Oncology (2022)

TPS207 Background: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) analogs or receptor antagonists is a cornerstone of prostate cancer treatment. As disease progresses, agents with complementary mechansims are co-prescribed with ADT to suppress extra-testicular testosterone production or block androgen receptors on cancer cells. Relugolix (120 mg) is an oral non-peptide GnRH receptor antagonist approved in the US for the treatment of aPC. In the phase 3 study, relugolix maintained suppression of testosterone to castration levels in 96.7% of men for up to 48 weeks (wks), with superiority to leuprolide acetate. Relugolix was well tolerated and associated with a 54% lower risk of major adverse cardiovascular events relative to leuprolide acetate (Shore N, NEJM 2020;382;23). To formally assess the safety and tolerability of combination treatment with relugolix, a phase 1 study in men with aPC has been undertaken. Methods: This is a three-part, open-label, parallel-cohort safety and tolerability study of relugolix in combination with abiraterone acetate in men with metastatic castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) (Part 1), apalutamide in men with mCSPC or non-metastatic catration-resistant prostate cancer (nmCRPC) (Part 2), or docetaxel in men with mCSPC or mCRPC (Part 3). Each part of the study consists of a 45-day screening period, a 12-wk primary study treatment period and a 40-wk safety extension treatment period. All of the men are required to have been treated with leuprolide acetate or a GnRH receptor antagonist (eg, degarelix) in combination with abiraterone acetate for a minimum of 12 wks, apalutamide for a minimum of 6 wks, or docetaxel for a minimum of one treatment cycle prior to the baseline (Day 1) visit. Men will be transitioned from leuprolide acetate or degarelix to relugolix (120 mg [Part 1 and 3] or 240 mg [Part 2] once daily after a single loading dose of 360 mg); on the approximate date the next analog or antagonist injection is scheduled; treatment with each combination treatment will continue as previously prescribed. Hence, the study will provide safety and tolerability of relugolix and the three different combination agents for up to 1 year and in addition, will provide safety and tolerability data as men transition from injectable leuprolide acetate or degarelix to oral treatment with relugolix. Enrollment into the study began in March 2021. A protocol amendment was approved in July 2021 to include Part 2 and Part 3 of the study and to add the 40-wk safety extension treatment period. Screening for Part 2 was initiated in August 2021 and for Part 3 it is expected to initiate in January 2022. Clinical trial information: NCT04666129.
Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma
Authors: Vijay Kodumudi, Lorin A Bibb, Jonas A Adalsteinsson, Neda Shahriari, Lauren Skudalski, Sueheidi Santiago, Jane M Grant-Kels, Jun Lu
Journal: Journal of the American Academy of Dermatology (2022)
AMAGRAMS
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL
Authors: Sujan Piya, Yaling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Mu, Hua He, Vivian Ruvolo, Natalia Baran, R. Eric Davis, Abhinav K. Jain, Marina Konopleava, Hagop Kantarjian, Michael Andreeff, M. James You, Gautam Borthakur
Journal: Leukemia (2022)

Abstract The NOTCH1-MYC-CD44 axis integrates cell-intrinsic and extrinsic signaling to ensure the persistence of leukemia-initiating cells (LICs) in T-cell acute lymphoblastic leukemia (T-ALL) but a common pathway to target this circuit is poorly defined. Bromodomain-containing protein 4 (BRD4) is implicated to have a role in the transcriptional regulation of oncogenes MYC and targets downstream of NOTCH1 , and here we demonstrate its role in transcriptional regulation of CD44 . Hence, targeting BRD4 will dismantle the NOTCH1-MYC-CD44 axis. As a proof of concept, degrading BRD4 with proteolysis targeting chimera (PROTAC) ARV-825, prolonged the survival of mice in Notch1 mutated patient-derived xenograft (PDX) and genetic models (ΔPTEN) of T-ALL. Single-cell proteomics analysis from the PDX model, demonstrated quantitative reduction of LICs (CD34+ CD7+ CD19−) and downregulation of the NOTCH1-MYC-CD44 axis, along with cell cycle, apoptosis and PI3K/Akt pathways. Moreover, secondary transplantation from PDX and ΔPTEN models of T-ALL, confirmed delayed leukemia development and extended survival of mice engrafted with T-ALL from ARV-825 treated mice, providing functional confirmation of depletion of LICs. Hence, BRD4 degradation is a promising LIC-targeting therapy for T-ALL.
NETHERLANDS
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exposure of midwives to nitrous oxide in four hospitals
Authors: K Macdonald, K Kenicer, Robyn Richmond, Ian Webster
Journal: BMJ (1986)

Blood cotinine, carboxyhaemoglobin, and thiocyanate concentrations and cigarette consumptionIt is important that doctors should be aware of the correlation between patients' blood concentrations of tobacco products, reported cigarette 1 Richmond RL, Austin A, Webster IW. Three year evaluation of a p amme by general practitioners to help patients to stop smolting.BrMedJ 1986;
Toll-Like Receptors on Tumor Cells
Journal: Cancer Research (2005)

In the article on Toll-like receptors on tumor cells in the June 15, 2005 issue of Cancer Research (1), Dr. Sun-Hsia Chen's name was mistakenly omitted from the list of authors. The list of authors should have read as follows: Bo Huang, Jie Zhao, Hongxing Li, Kai-Li He, Yibang Chen, Shu-Hsia Chen, Lloyd Mayer, Jay C. Unkeless, and Huabao Xiong. Dr. Chen's affiliation is the Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York. This study, Dr. Huang, and Dr. Chen were supported by NCI Grants CA70337 and CA84404 and by the Sharp Foundation (to S.H. Chen).
Address in Surgery
Authors: Wm. H. Hingston
Journal: BMJ (1892)

speculation.But at the same time it behoves all those con- cerned in its guidance, or responsible for the instruction of those who are to become its members, to bear in mind its position as one of the main supports of the tripod of learning, as one of the great factors in the intellectual progress of humanity; being well assured that it cannot sacrifice any portion of its intellectual elevation and dignity without a corresponding sacrifice of its truest and most practical usefulness.
Hallux Valgus
Authors: P A KOENIG
Journal: BMJ (1965)

M Jou 1623certain deep partial-loss burns.S. Sevitt' confirmed these findings in animal experiments, and the pin-prick test has now been established as a useful clinical guide.'Another group of tests has been based on survival of vascular supply.T. Gibson and A. Brown'0 described the use of a dye, Kiton fast green, given intravenously as a method for distinguishing between areas of partial-and full-thickness loss.This was further elaborated by M. N. Tempest," who used disulphine blue.Areas of partial-thickness loss are stained by the dye whereas those of whole-thickness loss remain uncoloured.Another variant on this method was described by J. A.
Real-world treatment patterns, survival outcomes, and health care resource utilization among individuals with nonmuscle-invasive bladder cancer in Canada.
Authors: Tamer N. Jarada, Geoffrey Gotto, Bimal Bhindi, Natalie Beaton, Tahir Feroz, Teagan Maier-Downing, Darren Brenner, Winson Y. Cheung, Devon J. Boyne
Journal: Journal of Clinical Oncology (2022)

470 Background: Real-world evidence pertaining to high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) is limited. We aimed to describe real-world treatment patterns and outcomes of this study population within a Canadian setting. Methods: A retrospective cohort study was conducted by linking various population-based administrative datasets from a large Canadian province. The study population consisted of all individuals ≥ 18 years who were diagnosed with Tis or high-grade Ta/T1 NMIBC in Alberta, Canada between 2010-2019. High-grade disease was defined using the WHO 1973 system. Individuals who initiated BCG therapy were classified as having received adequate induction therapy if they completed 5+ cycles. BCG unresponsive was defined as receipt of TURBT, intravesical chemotherapy, cystectomy, or radiation within 1 year of the last BCG dose. Overall survival (OS), cystectomy-free survival (CFS), progression-free survival (PFS), and healthcare resource utilization (HCRU) were examined from the time of being classified as BCG unresponsive following adequate induction therapy. CFS was defined as time until death or radical cystectomy and PFS was defined as time until death or disease progression. Disease progression was classified using a proxy based on subsequent receipt of cystectomy, systemic therapy, or radiation. Kaplan-Meier survival curves were estimated for OS, CFS, and PFS and the mean number of healthcare encounters within each year of follow-up were estimated for HCRU. Results: 5369 individuals were diagnosed with NMIBC in Alberta between 2010-2019, of whom 2679 (49.9%) had Tis or HG Ta/T1 disease at initial diagnosis. Among individuals with high-risk NMIBC, 1044 (39%) initiated BCG therapy. 885 (84.8%) individuals received 5+ BCG doses. Despite receiving adequate induction treatment, 249 (28.1%) individuals became unresponsive. The mean age at BCG unresponsive was 72.9 years and 213 (58.5%) were males. Among those who were BCG unresponsive, 25.7% underwent radical cystectomy (median time to cystectomy: 4.4 months, IQR: 1.7 to 8.2). Median OS was 50.7 months (95% CI: 37.2-65.5), CFS was 22.4 months (18.9-31.1), and PFS was 14.4 months (11.6-20.9). Within the first year of becoming BCG unresponsive, individuals spent an average of 6.2 days in hospital, had 28.8 visits with healthcare practictitioners, and had 2.2 emergency and 13.6 non-emergency encounters with ambulatory care services. Conclusions: A considerable proportion of individuals with high-risk NMIBC became unresponsive to BCG therapy despite adequate treatment. The time from becomining BCG unresponsive to radical cystectomy was relatively short. These findings highlight an unmet need in this patient population for alternative therapeutic options.
THE RELATIONS OF SCIENTISTS TO NEWSPAPERS.MEDICAL ORATORY.
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of HMOs
Journal: JAMA (1984)

<h3>To the Editor.—</h3> Drs Jackson-Beeck and Kleinman present evidence of favorable self-selection among HMO enrollees in the Minneapolis area. Their findings, which have been supported in local studies,<sup>1,2</sup>will undoubtedly generate discussion between HMO advocates and opponents. But policymakers concerned with medical care cost containment must consider more than an enrollee's prior experience. The effectiveness of the HMO in controlling utilization immediately after the enrollee joins is a critical factor in judging the success of the HMO concept. Several important points should be clarified regarding the study by Roghmann et al<sup>1</sup>cited by Jackson-Beeck and Kleinman. This study involved persons who joined each of three prepaid plans introduced in Rochester, NY, in 1973. The inpatient hospital utilization experience was analyzed for calendar year 1972 (one year prior to joining) and calendar years 1974 and 1975 (the two years after enrollment). The object of this study was to control
Suicide
Authors: E. B. Strauss
Journal: BMJ (1956)

A surgeon, I suppose, is more upset by a death on the table than by anything else.Most psychiatrists feel the loss of a patient by suicide as the most distressing professional accident, although in so many instances, even if a suicidal attempt (" successful " or otherwise) is predictable, we know it to be unavoidable.Suicide can be studied from a great number of aspects: clinical, statistical, historical, psycho-analytical, social-psychological, forensic, ecological, moral, and anthropological.I would like briefly to discuss suicide as an anthro- pological problem, using the word anthropology in a very wide sense, so as to include ecology, social psychology, religion, and ethics.Although a great deal has been written on the subject of suicide, two works stand out as being of special importance: (1) Le Suicide by the late Professor Durkheim, published as long ago as 1897, and (2) Suicide in London, An Ecological Study, by Peter Sainsbury, published in 1955.The interesting feature, to my mind, about Dr. Sainsbury's valuable Maudsley monograph is that it so amply confirms the views of the well-known professor of sociology at the Sorbonne.Before getting down to my main thesis, it would be as well, perhaps, to get the clinical aspects of suicide out of the way in as few words as possible by briefly considering suicide and attempted suicide from the strictly psychiatric point of view.I shall precede these clinical remarks by trying to dispel a false impression which is almost superstitiously held by so many doctors and laymen alike: if a patient " talks " suicide, he is unlikely to attempt it.Nothing could be further from the truth. Associated Mental DisordersThe mental disorders which stand out as being especially associated with a suicidal risk are: (1) cyclophrenia, as I prefer to call manic-depressive psychosis; (2) involutional depression, particularly the agitated form; (3) schizophrenia; (4) paraphrenia; (5) inadequate psychopathy; and (6) re- active and post-infective depressive states.Anorexia nervosa, about which condition I have very individual views, is, of course, a slow attempt at suicide, but it is outside the scope of this paper.
Abstract 294: Alterations in Cerebral Mitochondrial Dynamics and Mitochondrial Mass After Successful Cardiopulmonary Resuscitation in a Porcine Model of Pediatric Cardiac Arrest
Authors: Kumaran Senthil, Marco M Hefti, Michael Karlsson, Ryan W Morgan, Johannes Ehinger, Constantine D Mavroudis, Vinay M Nadkarni, Robert A Berg, Robert M Sutton, Francis X McGowan, Todd J Kilbaugh
Journal: Circulation (2018)

Introduction: A critical convergence point for neurologic injury following cardiac arrest is cerebral mitochondrial (Mt) dysfunction, regulated by Mt dynamics (balance of fusion and fission). Both fusion and fission are important to Mt homeostasis under normal conditions; however, under stress fission can decrease Mt mass and signal apoptosis, while fusion promotes oxidative phosphorylation efficiency. Our group has previously shown hemodynamic directed CPR (HD-CPR) improves Mt bioenergetics compared to AHA depth-guided CPR (DG-CPR), which correlated with better neurologic function. Hypothesis: Compared to DG-CPR, HD-CPR will result in cerebral cortical protein expression consistent with Mt fusion and preservation of mitochondrial mass 24 hours post-ROSC. Methods: One-month-old piglets were designated into three groups: 1) DG-CPR (n=5); 2) HD-CPR (n=5; goal SBP 90 mmHg, goal coronary perfusion pressure 20mmHg); 3) Shams (n=7). Groups 1 and 2 underwent 7 minutes of asphyxia, VF, 10-20 min of CPR, and post-ROSC therapies to maintain hemodynamic, oxygenation and ventilation goals. The primary outcomes were immunoblot quantification of cortical proteins for fusion (Opa-1, Opa-1 long to short chain ratio, MFN-2), fission (DRP-1), and citrate synthase activity for Mt mass. Groups shown as median and IQR and analyzed by Kruskal-Wallis, then Dunn’s multiple comparisons. Results: HD-CPR subjects had increased total Opa-1 expression compared to sham (1.52 [1.02,1.69] vs. 0.47 [0.34,0.51], p=0.001). Opa-1 long to short chain ratio was higher in HD-CPR than both sham (0.64 [0.46,0.92] vs. 0.28 [0.25,0.36], p=0.025) and DG-CPR (0.26 [0.26,0.31], p=0.018). There were no differences in MFN-2 or DRP-1 expression between groups. Mt mass was lower in DG-CPR than sham (11.02 [10.15,12.29] vs. 13.9 [12.35,15.63], p=0.029), but preserved in HD-CPR. Discussion: Piglets treated with HD-CPR exhibited protein expression consistent with Mt fusion, as evidenced by upregulation of total Opa-1, elevated Opa-1 long to short chain ratio, and preservation of Mt mass compared to standard AHA depth guided CPR strategy. We speculate that neurotherapeutics that target Mt dynamics could further improve brain Mt bioenergetics and neurologic function after pediatric CA.
Arterial puncture.
Authors: D C Flenley
Journal: BMJ (1980)

To determine* Abnormalities in gaS -exchanging functions of lungs and in acid-base state To diagnose Respiratory failure iype Po2 low Pco2 lovv-normal Arterial puncture is carried out in order to measure the arterial blood-gas tensions (Pao2 and Paco,), oxygen saturation (Sao2), and pH (or [H+]) so as to determine (1) abnormalities in the gas exchanging function of the lungs, for which it is necessary to know also the concentr'ation of oxvygen being inspired at the time of puncture; and (2) the patient's acid-base state, by relating the PaCO2 to the pH (or [H+]), both to diagnose a disorder and as a guide to its treatment.Arterial puncture is thus essential for the accurate diagnosis of respiratory failure, which may have been suspected clinically by noting central cyanosis.Only by knowing arterial blood-gas tensions can the type of respiratory failure be identified-for example, type I with a low Po2 and normal or lOW PCo2; or type II, in which a low Po2 is associated with a high PCo2.As the management of these two conditions may differ considerably, accurate diagnosis is essential.Although measurement of the venous bicarbonate concentration will give some indication of the severity of a metabolic acid-base disturbance, definition of the type and severity of a respiratory acid-base disturbance can be made only when arterial Pco2 and pH (or [H+]) are known. P02 low Pco2 highContraindications Contraindications to arterial puncture include a bleeding diathesis, as for example a platelet count below 3 x 1010/1 (30 000/MM3); and disturbance of clotting factors as in haemophilia and hypoprothrombinaemia or after overdoses of antic-oagulants such as heparin etc.In these conditions arterial puncture may lead to an excessive local haematoma, and this -may also rarely complicate arterial puncture in patients with a diastolic blood pressure over 120 mm Hg..Platelet count>..... ..